新型冠状病毒病所致肺纤维化中中西医结合的疗效和安全性：贝叶斯网状Meta 分析方案。
Efficacy and safety of the combination of modern medicine and traditional Chinese medicine in pulmonary fibrosis caused by novel coronavirus disease: A protocol for Bayesian network meta-analysis.
机构信息
First College of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Department of Health Care, Huaiyin People's Hospital, Jinan City, Shandong Province, China.
出版信息
Medicine (Baltimore). 2021 Dec 23;100(51):e28282. doi: 10.1097/MD.0000000000028282.
BACKGROUND
Novel coronavirus disease (COVID-19) is a kind of pulmonary inflammation induced by New Coronavirus. It seriously threatens people's health and safety. Clinical studies have found that some patients have different degrees of inflammation after discharge from hospital, especially in patients with severe inflammatory lung fibrosis. Early combination of Chinese medicine and modern medicine has important clinical significance. There are still many deficiencies in the current research. We studied the effectiveness of the combination of traditional Chinese medicine and modern medicine in the treatment of pulmonary fibrosis caused by COVID-19, and proposed a network meta-analysis (NMA) scheme.
METHODS
According to the search strategy, we will search Chinese and English databases to collect all randomized controlled trials of traditional Chinese medicine combined with modern drugs or only using traditional Chinese medicine for new coronavirus-19-induced pulmonary fibrosis between December 1, 2019 and November 15, 2021. First, the literature was screened according to the eligibility criteria, endnotex9 was used to manage the literature, and the Cochrane Collaboration's tool was used to assess the quality of the included literature. Revman 5.3, Stata 14.2, and gemtc14.3 meta-analysis software was then used for data processing and analysis, and the grading of recommendations assessment will be used to develop and evaluate a hierarchy for classifying the quality of evidence for NMA.
RESULTS
Through the analysis, the ranking of efficacy and safety of various treatments for pulmonary fibrosis caused by COVID-19 will be drawn, thus providing stronger evidence support for the choice of clinical treatment methods.
CONCLUSION
Traditional Chinese medicine (TCM) combined with modern drugs has played a positive role in the treatment of pulmonary fibrosis caused by COVID-19, and this study may provide more references for the clinical medication of pulmonary fibrosis caused by COVID-19.
INPLASY REGISTRATION NUMBER
INPLASY2021110061.
背景
新型冠状病毒病（COVID-19）是一种由新型冠状病毒引起的肺部炎症，严重威胁着人们的健康和安全。临床研究发现，部分患者出院后存在不同程度的炎症，特别是重症炎症肺纤维化患者。早期中西医结合治疗具有重要的临床意义，但目前研究仍存在较多不足。我们研究了中药联合现代医学治疗新型冠状病毒肺炎肺纤维化的疗效，并提出了网络荟萃分析（NMA）方案。
方法
根据检索策略，我们将检索 2019 年 12 月 1 日至 2021 年 11 月 15 日期间中英文数据库中所有关于中药联合现代药物或仅使用中药治疗新型冠状病毒肺炎肺纤维化的随机对照试验。首先根据纳入标准筛选文献，使用 Endnotex9 管理文献，采用 Cochrane 协作工具评价纳入文献的质量。然后使用 Revman 5.3、Stata 14.2 和 gemtc14.3 荟萃分析软件进行数据处理和分析，并采用推荐评估分级法（Grading of Recommendations Assessment，GRADE）对 NMA 的证据质量进行分级和评价。
结果
通过分析，将得出各种治疗 COVID-19 引起的肺纤维化的疗效和安全性的排序，从而为临床治疗方法的选择提供更强有力的证据支持。
结论
中药联合现代药物在治疗 COVID-19 引起的肺纤维化方面发挥了积极作用，本研究可为 COVID-19 引起的肺纤维化的临床用药提供更多参考。
INPLASY 注册号：INPLASY2021110061。
Zotero 插件